Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
Volume 0.58M
Average 0.33M
DMRA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Damora Therapeutics, Inc.NASDAQ: DMRA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $6.97M rose 262.6% year over year, ahead of the +63.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 71.2% from the prior quarter. Over 3 fiscal years it compounded at -8.2% a year.
Context
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -6.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.97M+71.2% QoQ
- Last fiscal yearDec 2025
- $9.69M-6.1% YoY
- LTMMar 2026
- $14.73M+63.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +262.6% | -100.0% | -362.6 pp |
| 1 year | -6.1% | -100.0% | -93.9 pp |
| 3-year CAGR | -8.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 9.69M USD
- Year-over-year change
- -6.1%
- 4-year CAGR
- -7.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.69M | -6.1% |
| FY2024 | 2024-12-31 | 10.32M | -13.0% |
| FY2023 | 2023-12-31 | 11.86M | -5.2% |
| FY2022 | 2022-12-31 | 12.51M | -5.9% |
| FY2021 | 2021-12-31 | 13.3M | — |
Selling, General & Admin vs competitors
How DMRA compares with its peers on the latest reported figures
- DMRA's LTM Mar 2026 selling, general & admin of $14.73M is the 8th highest of the 9 companies compared; the peer median is $100.71M.
- Its year-over-year change of +63.7% is the highest of 7, against a peer median of +10.9%.
- Over three fiscal years its annual growth of -8.2% compares with a peer median of +11.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.4B | +8.2% | +11.2% | 24.0% | |
| LTM Jun 2026 | $726.99M | — | -39.2% | 17.6% | |
| LTM Mar 2026 | $154.66M | -2.5% | +54.0% | 78.9% | |
| LTM Mar 2026 | $118.84M | +5.8% | +1.0% | 39.6% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $82.59M | +51.8% | +67.0% | — |
| LTM Mar 2026 | $71.65M | +50.0% | +6.1% | 396.0% | |
| LTM Mar 2026 | $46.5M | +13.6% | +19.4% | 140.1% | |
DMRADamora Therapeutics, Inc. | LTM Mar 2026 | $14.73M | +63.7% | -8.2% | — |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $10.49M | — | — | — |
| Peer median (excluding DMRA) | $100.71M | +10.9% | +11.2% | 59.3% | |
Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 441K | 490K | 830K | 181K | 0 |
| Gross Profit | (441K) | (490K) | (830K) | (181K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.49M | 48.21M | 23.77M | 6.4M | 201.19M |
| Selling, General & Admin | 13.3M | 12.51M | 11.86M | 10.32M | 9.69M |
| Operating Expenses | 51.79M | 60.72M | 35.63M | 16.72M | 210.87M |
| Depreciation & Amortization | 441K | 490K | 830K | 181K | 34K |
| EBITDA | (51.31M) | (61.13M) | (37.52M) | (21.22M) | (209.76M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (52.23M) | (61.21M) | (36.46M) | (16.9M) | (210.87M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 156K | 722K | 1.69M | 844K | 1.17M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 475K | (417K) | (1.89M) | (4.5M) | 1.08M |
| Income Before Tax | (51.75M) | (61.62M) | (38.35M) | (21.4M) | (209.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 41K | 50K |
| Net Income | (51.75M) | (61.62M) | (38.35M) | (21.44M) | (209.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (51.22) | (60.63) | (36.08) | (18.53) | (158.13) |
| EPS (Diluted) | (51.22) | (60.63) | (36.08) | (18.53) | (158.13) |
| Weighted Avg Shares | 1.01M | 1.02M | 1.06M | 1.16M | 1.33M |
| Weighted Avg Shares (Diluted) | 1.01M | 1.02M | 1.06M | 1.16M | 1.33M |
Damora Therapeutics, Inc.
NASDAQ:DMRA
Intrinsic Alpha fair value
Locked
Current Price
$22.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.